Charles Bennett to Drug Costs
This is a "connection" page, showing publications Charles Bennett has written about Drug Costs.
Connection Strength
4.079
-
Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019 04; 24(4):537-548.
Score: 0.603
-
Why California's Proposition 61 Was a Bad Idea. Am J Med. 2017 08; 130(8):882-884.
Score: 0.530
-
Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA. Lancet Oncol. 2017 01; 18(1):22-23.
Score: 0.519
-
Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door. J Clin Oncol. 2016 12 20; 34(36):4320-4322.
Score: 0.513
-
Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment. JAMA Oncol. 2016 Feb; 2(2):274-6.
Score: 0.487
-
Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis. J Natl Cancer Inst. 2013 Aug 07; 105(15):1072-3.
Score: 0.408
-
Humira: the first $20 billion drug. Am J Manag Care. 2023 02; 29(2):78-80.
Score: 0.198
-
Pricing, profits and pharmacoeconomics--for whose benefit? Expert Opin Pharmacother. 2001 Mar; 2(3):377-83.
Score: 0.173
-
The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: results from the 1997 American Society of Clinical Oncology survey. Health Services Research Committee of the American Society of Clinical Oncology. Ann Oncol. 1999 Nov; 10(11):1355-9.
Score: 0.158
-
Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done? JAMA Oncol. 2019 03 01; 5(3):297-298.
Score: 0.151
-
Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition. Drugs. 2018 Nov; 78(17):1777-1781.
Score: 0.147
-
Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers? Clin Perform Qual Health Care. 1995 Jul-Sep; 3(3):156-64.
Score: 0.117
-
Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999 Sep; 24(5):555-60.
Score: 0.039
-
Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma. Acta Oncol. 1999; 38(8):1063-7.
Score: 0.037